TP53 (Tumor Protein p53 "Guardian of the Genome" Master Tumor Suppressor Gene)
TP53 (tumor protein p53; HGNC:11998, NCBI Gene ID 7157) is a human locus mapped to chromosome band 17p13.1 that encodes homotetrameric sequence-specific transcription factor p53 (393 aa; 53 kDa). TP53 acts in ATM/ATR/p14ARF stress sensing -> CDKN1A (p21) G1 arrest, DNA repair, BAX/PUMA apoptosis, ferroptosis & senescence, together with p53 Tumor Suppressor Protein Structure, MDM2 (Primary E3 Ubiquitin Ligase Antagonist of p53), and CDKN1A (p21 Direct Cell-Cycle Effector of p53). Tumor suppressor regulating cell cycle arrest, DNA repair, cellular senescence, and apoptosis in response to genomic stress.
Somatically mutated in >50% of all human cancers; germline heterozygous mutations cause Li-Fraumeni syndrome
Gene Structure & Expression
Genomic Organization & Cytogenetic Locus: 11-exon gene spanning 20 kb on chromosome 17p13.1 encoding a 393-amino-acid polypeptide composed of two N-terminal transactivation domains (TAD1 residues 1–40 binding MDM2; TAD2 residues 41–61), a proline-rich domain (containing the common codon 72 Arg/Pro polymorphism), a central zinc-coordinated immunoglobulin-like sequence-specific DNA-binding domain (residues 94–292, where >85% of cancer missense mutations cluster), a nuclear localization and tetramerization domain (residues 325–356), and a basic C-terminal regulatory domain.
Cellular & Tissue Expression Profile: Constitutively transcribed in all somatic cells, but in unstressed cells the p53 protein is kept at ultra-low levels (half-life ~5–20 minutes) via continuous ubiquitylation by its negative-feedback E3 ligase MDM2 and proteasomal degradation.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: Upon DNA double-strand breaks (sensed by ATM/CHK2), replication fork stalling (ATR/CHK1), or oncogenic hyperproliferation (p14ARF encoded by CDKN2A), phosphorylation of p53 at Ser15/Ser20 and sequestration of MDM2 stabilize nuclear p53 tetramers, which bind decameric 5-prime-RRRCWWGYYY-3-prime half-sites to activate CDKN1A (p21, halting the cell cycle), GADD45A/DDB2 (DNA repair), TIGAR (antioxidant metabolism), GDF15, or—if damage is irreparable—pro-apoptotic BAX, BBC3 (PUMA), and PMAIP1 (NOXA).
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: The single most frequently mutated gene in human oncology (inactivated in >50% of all sporadic tumors and >95% of high-grade serous ovarian carcinomas, with six DNA-binding hotspot codons: Arg175, Gly245, Arg248, Arg249, Arg273, and Arg282); germline heterozygous TP53 mutations cause autosomal dominant Li-Fraumeni syndrome with near-100% lifetime cancer penetrance, whereas elephants carry ~20 retroduplicated TP53 copies (EP53) that enforce hyper-sensitive apoptosis and Peto-paradox cancer resistance.
Therapeutic & Clinical Pharmacology: Targeted clinically by small-molecule MDM2-p53 antagonists (idasanutlin, navtemadlin, brigimadlin) in TP53-wild-type tumors and by mutant-p53 structural reactivators (such as rezatapopt / PC14586, which selectively refolds the Y220C pocket mutant into wild-type conformation).